Sciwind Biosciences Reports P-IIb Trial Interim Results of XW003 (ecnoglutide) for the Treatment of Obesity
Shots:
- The ongoing P-IIb trial of XW003 (1.2/1.8/2.4mg, qw) vs liraglutide (3.0mg, qd for 26wks.) in 206 patients with obesity at 9 sites in Australia & New Zealand. The study is expected to be completed at the end of 2022 with anticipated results in 2023
- The results showed that patients treated with XW003 (2.4mg, qw) achieved a mean body weight reduction from baseline of 11.1% (10.9 kg) vs 7.9% (8.1 kg), ≥5% & ≥10% body weight loss from baseline (88.5% for 2.4mg vs 70.4%) & (57.7% vs 33.3%), favorable trends were also observed for other efficacy parameters
- The therapy was safe & well tolerated, the AE profile was consistent with other GLP-1 drugs, and patients reporting any AE during the treatment period were similar among 4 treatment groups after 18wks.
Ref: PR Newsswire | Image: Sciwind
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
